![]() | |
Clinical data | |
---|---|
Trade names | Emdabol, Embadol, Emdabolin, Protabol |
Other names | Thiomesterone; Thiomestrone; StA 307 |
Routes of administration | Oral |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.016.923 |
Chemical and physical data | |
Formula | C24H34O4S2 |
Molar mass | 450.65 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Tiomesterone (INN, JAN; thiomesterone (BAN); also known as 1α,7α-bis(acetylthio)-17α-methylandrost-4-en-17β-ol-3-one; developmental code StA 307; brand names Emdabol, Embadol, Emdabolin, and Protabol) is a synthetic, orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of testosterone. [1] It was described in 1963. [1]
Fluorometholone, also known as 6α-methyl-9α-fluoro-11β,17α-dihydroxypregna-1,4-diene-3,20-dione, is a synthetic glucocorticoid which is used in the treatment of inflammatory eye diseases. The C17α acetate ester, fluorometholone acetate, is also a glucocorticoid and is used for similar indications.
Trestolone acetate is a synthetic and injected anabolic–androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone) which was never marketed. It is an androgen ester – specifically, the C17 acetate ester of trestolone. The medication was first described in 1963.
Flumedroxone is a steroidal progestogen of the 17α-hydroxyprogesterone group that was never marketed. The C17α acetate ester of flumedroxone, flumedroxone acetate, has been marketed as an antimigraine drug.
Enestebol (INN), also known as 4-hydroxy-17α-methyl-δ1-testosterone, as well as 4,17β-dihydroxy-17α-methylandrosta-1,4-dien-3-one, is a synthetic and orally active anabolic–androgenic steroid (AAS) and a 17α-alkylated derivative of testosterone which was never marketed. It is closely related to oxymesterone (4-hydroxy-17α-methyltestosterone), as well as to chlorodehydromethyltestosterone (4-chloro-17α-methyl-δ1-testosterone), methylclostebol (4-chloro-17α-methyltestosterone), and metandienone (17α-methyl-δ1-testosterone).
Hydroxystenozole (INN), also known as 17α-methylandrost-4-eno[3,2-c]pyrazol-17β-ol, is an orally active androgen/anabolic steroid (AAS) and a 17α-alkylated derivative of testosterone that was described in the literature in 1967 but was never marketed. It is closely related to stanozolol (17α-methyl-5α-androstano[3,2-c]pyrazol-17β-ol), differing from it only in hydrogenation.
Bolenol, also known as 17α-ethyl-19-norandrost-5-en-17β-ol (ethylnorandrostenol), is a synthetic, orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of 19-nortestosterone (nandrolone) that was never marketed. It was described in the literature in 1969.
Propetandrol (INN), or propethandrol, also known as 17α-ethyl-19-nortestosterone 3β-propionate or 17α-ethyl-19-nor-4-androstenediol 3β-propionate, as well as 17α-ethylestr-4-en-3β,17β-diol 3β-propionate, is a synthetic and orally active anabolic–androgenic steroid (AAS) and progestogen and a 17α-alkylated derivative of 19-nortestosterone. It is an androgen ester – specifically, the 3β-propionate ester of norethandrolone (17α-ethyl-19-nortestosterone).
Gestaclone, also known as 6-chloro-1α,2α:16α,17-bismethylene-4,6-pregnadiene-3,20-dione, is a steroidal progestin of unique chemical structure derived from progesterone that was first described in 1967 and was never marketed.
Oxabolone is a synthetic anabolic-androgenic steroid (AAS) of the nandrolone (19-nortestosterone) group which was never marketed. It can be formulated as the cipionate ester prodrug oxabolone cipionate, which, in contrast, has been marketed for medical use.
Hydromadinone acetate, also known as chloroacetoxyprogesterone (CAP), as well as 6α-chloro-17α-acetoxyprogesterone or 6α-chloro-17α-acetoxypregn-4-ene-3,20-dione, is a steroidal progestin of the 17α-hydroxyprogesterone group that was never marketed. It is the C17α acetate ester of hydromadinone, which, similarly, was never marketed.
Anagestone (INN), also known as 3-deketo-6α-methyl-17α-hydroxyprogesterone or as 6α-methyl-17α-hydroxypregn-4-en-20-one, is a progestin which was never marketed.
Flugestone, also known as flurogestone, as well as 9α-fluoro-11β,17α-dihydroxyprogesterone, is a steroidal progestin of the 17α-hydroxyprogesterone group that was never marketed. An acetate ester, flurogestone acetate, is used in veterinary medicine.
Etamestrol (INN), or eptamestrol, also known as 7α-methyl-19-nor-17α-pregna-1,3,5(10)-trien-20-yne-1,3,17-triol 1,3-dibenzoate, is a synthetic, steroidal estrogen described as an ovulation inhibitor that was synthesized in 1979 but was never marketed.
Cismadinone (INN), also known as 6α-chloro-17α-hydroxypregna-1,4-diene-3,20-dione or 6α-chloro-δ1-dehydro-17α-hydroxyprogesterone, is a steroidal progestin closely related to the 17α-hydroxyprogesterone derivatives that was never marketed. An acetylated form, cismadinone acetate, also exists, but similarly to cismadinone, was never marketed.
Cismadinone acetate, also known as 6α-chloro-δ1-dehydro-17α-acetoxyprogesterone or as 6α-chloro-17α-acetoxypregna-1,4-diene-3,20-dione, is a steroidal progestin related to the 17α-hydroxyprogesterone derivatives which was never marketed. It is the acetylated form of cismadinone, which is also a progestin but, similarly to cismadinone acetate, was never marketed.
Stenbolone acetate (USAN), also known as 2-methyl-4,5α-dihydro-δ1-testosterone 17β-acetate or as 2-methyl-5α-androst-1-en-17β-ol-3-one 17β-acetate, is a synthetic, injected anabolic–androgenic steroid (AAS) and derivative of dihydrotestosterone (DHT) which has been marketed in Spain.
Methandriol diacetate, or methylandrostenediol diacetate, also known as 17α-methylandrost-5-ene-3β,17β-diol 3β,17β-diacetate, is a synthetic, injected anabolic–androgenic steroid (AAS) and a 17α-alkylated derivative of 5-androstenediol that was never marketed. It is an androgen ester – specifically, the C3,17β diacetate ester of methandriol (17α-methyl-5-androstenediol) – and acts as a prodrug of methandriol in the body.
Nisterime (INN), also known as 2α-chloro-4,5α-dihydrotestosterone 3-O-(p-nitrophenyl)oxime or as 2α-chloro-5α-androstan-17β-ol-3-one 3-O-(p-nitrophenyl)oxime, is a synthetic anabolic-androgenic steroid (AAS) and a derivative of dihydrotestosterone (DHT) that was never marketed. The C17α acetate ester of nisterime, nisterime acetate (ORF-9326), also exists and was developed as a postcoital contraceptive but was similarly never marketed.
6α-Methyl-17α-bromoprogesterone is a steroidal progestin related to haloprogesterone (6α-fluoro-17α-bromoprogesterone) that was described in 1963 and was never marketed.
Methyltestosterone 3-hexyl ether, or 17α-methyltestosterone 3-hexyl enol ether, also known as 17α-methylandrost-3,5-dien-17β-ol-3-one 3-hexyl ether, is a synthetic anabolic-androgenic steroid and an androgen ether – specifically, the 3-hexyl ether of methyltestosterone.